Medical Expert and Managing Partner- Scott Rocklage

Myotonic dystrophy 1 or also known as DM type 1 is known to be the leading cause of muscular dystrophy mainly in adul

Myotonic dystrophy 1 or also known as DM type 1 is known to be the leading cause of muscular dystrophy mainly in adults. To fight the disorder Expansion Therapeutics has been raising funds to fight the genetic disorder. The pharmaceutical company has added about $55.3 million for the purpose of fighting the diseases. According to medical experts, the symptoms are observed when the RNA has reached the toxic level. Several organizations participated in the fundraising among them; RA Capital, Sanofi Ventures, Kleiner Perkins, Novartis Ventures Fund, and Alexandria Venture Investment.

 

Experts explain that RNA are molecules that are genetically transferred and then converted to proteins and when it reaches the toxic level the DM1 condition happens. In the case when the toxic level is reached the body systems are affected including the heart, the respiratory system, central nervous system, gastrointestinal system, as well as hormonal system. DM1 is a generational disease which does not have any treatment according to medical experts. Expansion Therapeutics is in the front line of providing medication for RNA. Expansion IS very much concern and does everything to fight and create a medication for expansion repeat disorder which is hereditary and does not respond to medical treatment. Medical researchers say that the diseases are caused by tiny portions of DNA which repeat themselves.

 

Scott Rocklage went through high school and after his graduation, he joined the University of California at Berkeley where he graduated with a Bachelors of Science (BS) in Chemistry. Mr. Rocklage later went for his Doctor of Philosophy (Ph.D.) in Chemistry from the Massachusetts Institute of Technology (MIT). For over 30 years Rocklage has been practicing medicine and his experience, as well as skills, have given him a responsibility of taking candidate drugs to clinical tests. Scott is a leader who has shown exemplary character and results in his leadership. He has been the President and the Chief Executive Officer of Nycomed Salutar, and Cubist Pharmaceuticals among other positions. Scott Rocklage joined 5 AM Ventures in 2003 as a venture partner. His hard work and commitment enabled him to climb the career ladder and he was promoted to the position of a Managing Partner within a year. Scott advises people to stay true to their ventures and goes further to say that venturing away from their strengthens makes them only do what is easy than what is right.

ts. To fight the disorder Expansion Therapeutics has been raising funds to fight the genetic disorder. The pharmaceutical company has added about $55.3 million for the purpose of fighting the diseases. According to medical experts, the symptoms are observed when the RNA has reached the toxic level. Several organizations participated in the fundraising among them; RA Capital, Sanofi Ventures, Kleiner Perkins, Novartis Ventures Fund, and Alexandria Venture Investment. Learn more: https://www.linkedin.com/in/scott-rocklage-66aa7a12a

 

Experts explain that RNA are molecules that are genetically transferred and then converted to proteins and when it reaches the toxic level the DM1 condition happens. In the case when the toxic level is reached the body systems are affected including the heart, the respiratory system, central nervous system, gastrointestinal system, as well as hormonal system. DM1 is a generational disease which does not have any treatment according to medical experts. Expansion Therapeutics is in the front line of providing medication for RNA. Expansion IS very much concern and does everything to fight and create a medication for expansion repeat disorder which is hereditary and does not respond to medical treatment. Medical researchers say that the diseases are caused by tiny portions of DNA which repeat themselves.

 

Scott Rocklage went through high school and after his graduation, he joined the University of California at Berkeley where he graduated with a Bachelors of Science (BS) in Chemistry. Mr. Rocklage later went for his Doctor of Philosophy (Ph.D.) in Chemistry from the Massachusetts Institute of Technology (MIT). For over 30 years Rocklage has been practicing medicine and his experience, as well as skills, have given him a responsibility of taking candidate drugs to clinical tests. Scott is a leader who has shown exemplary character and results in his leadership. He has been the President and the Chief Executive Officer of Nycomed Salutar, and Cubist Pharmaceuticals among other positions. Scott Rocklage joined 5 AM Ventures in 2003 as a venture partner. His hard work and commitment enabled him to climb the career ladder and he was promoted to the position of a Managing Partner within a year. Scott advises people to stay true to their ventures and goes further to say that venturing away from their strengthens makes them only do what is easy than what is right.